Here's why the Creso Pharma (ASX:CPH) share price is up 7%

Good news out of the Creso Pharma camp this morning.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price has climbed well into the green in early trade today.

Cresco Pharma shares are now exchanging hands at 11.75 cents apiece, an almost 7% gain from the open.

What is Creso Pharma?

Creso Pharma develops and commercialises pharmaceutical cannabis and psychedelic compounds to treat health and medical conditions.

The company has a wide footprint across Switzerland, Australia, Canada, Colombia and Israel, but realises most revenue from Europe and the Middle East.

Creso Pharma has a market capitalisation of $131 million at the time of writing.

What's behind today's gains?

Creso provided an update on "operational progress" achieved through its Canadian subsidiary, Halucenex Life Sciences.

Halucenex is a research company focused on developing novel psychedelic compounds. These products are then sold to the pharmaceutical markets.

Creso announced that Halucenex has completed all satisfactory requirements for USP 61 microbial enumeration testing.

This is a significant milestone that demonstrates Creso's psilocybin compound is of pharmaceutical grade and safe from microbial nasties.

Furthermore, the company announced it had "commenced USP 62 protocols".

That is a similar test that examines pharmaceutical products for the presence of additional pathogens and other microbes.

It is an essential phase of any route to market in the pharmaceutical industry because the product must be deemed fit for humans.

Creso seems confident the test will "deem the company's products safe for human consumption" if successful.

What else does this mean?

Moreover, if successful, it will progress Halucenex's clinical trial authorisation (CTA) with Health Canada, helping to move forward its clinical trial pipeline.

Receiving the CTA allows the company to commence its phase II efficacy trial investigating the use of psilocybin in the treatment of post-traumatic stress disorder (PTSD).

Creso estimates the PTSD therapeutics market is worth "upwards of US$10.5 billion by 2025" and the company intends to "grow its market share across the sector" in the coming periods.

Market sentiment around clinical trial progress is a major force that drives share price returns in biotech and biopharma companies. That means good news is reflected on the charts for these shares.

In addition, Creso also released its quarterly update on Monday which shot its share price 9% higher on the day.

It stands to reason these two factors are behind the movement in the Creso Pharma share price today.

Creso Pharma share price snapshot

The Creso Pharma share price has posted a loss of 35% since January 1 this year. Over the last month, Creso shares have dipped 13% into the red.

Despite this, Creso shares have still climbed 279% into the green over the past 12 months.

This has outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of around 26% over the past year.

Contributor Zach Bristow has no position on any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Coronado, DroneShield, Lovisa, and Mayne Pharma shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »

Man pointing at a blue rising share price graph.
Share Gainers

Guess which ASX 300 stock just rocketed 43% on big news!

Investors are piling into this ASX 300 stock on Wednesday. But why?

Read more »

Three friends leaping in the air in joy with a dog on the ground.
Share Gainers

Can May's top 3 performing ASX 50 stocks repeat in June?

These three blue chip stocks led the pack in the month of May. Do brokers think they can back it…

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX was back to the races this Tuesday.

Read more »

A woman reaches her arms to the sky as a plane flies overhead at sunset.
Travel Shares

Why the Qantas share price soared 20% in May to new all-time highs

With another stellar month in May, Qantas shares are up more than 79% in a year.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why DroneShield, Judo, Pepper Money, and Strickland shares are surging today

These shares are having a good session on Tuesday. But why?

Read more »

Yellow rising arrow on a brick wall with a man on a ladder.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough start to the trading week for investors this Monday.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX 200 stock has rocketed 86% since April?

This sky rocketing ASX 200 stock continues to defy short sellers. But how?

Read more »